Background: The small-molecule MDM2 antagonist nutlin-3 has proved to be an effective p53 activating therapeutic compound in several preclinical cancer models, including acute myeloid leukemia (AML). We and others have previously reported a vigorous acetylation of the p53 protein by nutlin-treatment. In this study we aimed to investigate the functional role of this p53 acetylation in nutlin-sensitivity, and further to explore if nutlin-induced protein acetylation in general could indicate novel targets for the enhancement of nutlin-based therapy. Results: Nutlin-3 was found to enhance the acetylation of p53 in the human AML cell line MOLM-13 (wild type TP53) and in TP53 null cells transfected with wild type p53 cDNA. Stable isotope labeling...
By analyzing the cDNA obtained from 16 B-cell chronic lymphocytic leukemia (B-CLL) patient samples, ...
Wild-type p53 is commonly expressed in melanoma but does not appear to be effective in the induction...
Nutlin-3a is a small-molecule antagonist of p53/MDM2 that is being explored as a treatment for sarco...
Background: The small-molecule MDM2 antagonist nutlin-3 has proved to be an effective p53 activating...
AbstractThe small-molecule inhibitor of murine double minute (MDM-2), Nutlin-3, induced variable apo...
The small-molecule inhibitor of murine double minute (MDM-2), Nutlin-3, induced variable apoptosis i...
The small-molecule inhibitor of murine double minute (MDM-2), Nutlin-3, induced variable apoptosis i...
The small molecule inhibitor of the MDM2/p53 interaction Nutlin-3 is a promising anti-cancer agent, ...
p53 is a tumour suppressor protein involved in maintenance of genomic stability of the cell. Primari...
OBJECTIVE: It has been shown that SOCS-1 plays an important role in the proper control of cytokine/g...
The small molecule inhibitor of the MDM2/p53 interaction Nutlin-3 is a promising anti-cancer agent, ...
Wild-type p53 is commonly expressed in melanoma but does not appear to be effective in the induction...
By analyzing the cDNA obtained from 16 B-cell chronic lymphocytic leukemia (B-CLL) patient samples, ...
MDM2 is an important negative regulator of p53 tumor suppressor. In this study, we sought to investi...
The small molecule inhibitor of the MDM2/p53 interaction Nutlin-3 significantly up-regulated the ste...
By analyzing the cDNA obtained from 16 B-cell chronic lymphocytic leukemia (B-CLL) patient samples, ...
Wild-type p53 is commonly expressed in melanoma but does not appear to be effective in the induction...
Nutlin-3a is a small-molecule antagonist of p53/MDM2 that is being explored as a treatment for sarco...
Background: The small-molecule MDM2 antagonist nutlin-3 has proved to be an effective p53 activating...
AbstractThe small-molecule inhibitor of murine double minute (MDM-2), Nutlin-3, induced variable apo...
The small-molecule inhibitor of murine double minute (MDM-2), Nutlin-3, induced variable apoptosis i...
The small-molecule inhibitor of murine double minute (MDM-2), Nutlin-3, induced variable apoptosis i...
The small molecule inhibitor of the MDM2/p53 interaction Nutlin-3 is a promising anti-cancer agent, ...
p53 is a tumour suppressor protein involved in maintenance of genomic stability of the cell. Primari...
OBJECTIVE: It has been shown that SOCS-1 plays an important role in the proper control of cytokine/g...
The small molecule inhibitor of the MDM2/p53 interaction Nutlin-3 is a promising anti-cancer agent, ...
Wild-type p53 is commonly expressed in melanoma but does not appear to be effective in the induction...
By analyzing the cDNA obtained from 16 B-cell chronic lymphocytic leukemia (B-CLL) patient samples, ...
MDM2 is an important negative regulator of p53 tumor suppressor. In this study, we sought to investi...
The small molecule inhibitor of the MDM2/p53 interaction Nutlin-3 significantly up-regulated the ste...
By analyzing the cDNA obtained from 16 B-cell chronic lymphocytic leukemia (B-CLL) patient samples, ...
Wild-type p53 is commonly expressed in melanoma but does not appear to be effective in the induction...
Nutlin-3a is a small-molecule antagonist of p53/MDM2 that is being explored as a treatment for sarco...